Trial Profile
A retrospective, multicenter study in ibrutinib treated patients with Chronic-lymphocytic-leukaemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Aug 2016
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 01 Aug 2016 New trial record
- 07 Jun 2016 Primary endpoint (Progression- free survival) has not been met according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology